Proteomics and Metabolomics for AKI Diagnosis

Area of Science:

• Nephrology
• Biomarker Discovery
• Omics Technologies

Background:

• Acute kidney injury (AKI) is a common, severe condition in hospitalized patients with no effective treatments.
• Early detection and intervention are critical for improving AKI outcomes, necessitating reliable biomarkers.
• Distinguishing AKI-related molecular changes from underlying conditions like shock or sepsis is challenging.

Purpose of the Study:

• To review state-of-the-art proteomic and metabolomic technologies for AKI biomarker discovery.
• To highlight new bioinformatics approaches for analyzing molecular pathways and interactions in AKI.
• To discuss AKI-associated proteomic and metabolomic biomarkers and their pathophysiological context.

Main Methods:

• Review of current tissue and biofluid proteomic and metabolomic technologies.
• Description of bioinformatics tools for pathway and molecular interaction analysis.
• Synthesis of existing literature on AKI biomarkers.

Main Results:

• Omics technologies are rapidly expanding the repertoire of potential AKI biomarkers beyond proteins to include RNAs, lipids, and metabolites.
• Most current biomarkers lack clear definition within the AKI molecular context.
• Advanced bioinformatics aids in understanding complex molecular interactions and pathways in AKI.

Conclusions:

• Accurate and accessible biomarkers are essential for timely AKI management and outcome prediction.
• Further research is needed to define the molecular context and clinical utility of novel AKI biomarkers.
• Integrating omics data with bioinformatics analysis holds promise for advancing AKI biomarker discovery.